Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med. 2020 Sep 24;383(13):1218-1230. doi: 10.1056/NEJMoa2002788. Epub 2020 Sep 18.
N Engl J Med. 2020.
PMID: 32945632
Clinical Trial.
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH.
Massard C, et al. Among authors: blake haskins ja.
J Clin Oncol. 2016 Sep 10;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761. Epub 2016 Jun 6.
J Clin Oncol. 2016.
PMID: 27269937
Free PMC article.
Clinical Trial.
Item in Clipboard
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte RJ, Huang B, Costa N, Blake-Haskins JA, Grivas P.
Powles T, et al. Among authors: blake haskins ja.
Future Oncol. 2022 Jun;18(19):2361-2371. doi: 10.2217/fon-2021-1631. Epub 2022 Apr 13.
Future Oncol. 2022.
PMID: 35416053
Free article.
Review.
Item in Clipboard
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA.
Schram AM, et al. Among authors: blake haskins ja.
JAMA Oncol. 2023 Jan 1;9(1):29-39. doi: 10.1001/jamaoncol.2022.5218.
JAMA Oncol. 2023.
PMID: 36394867
Free PMC article.
Item in Clipboard
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA, Walker J.
Rebelatto MC, et al. Among authors: blake haskins ja.
Diagn Pathol. 2016 Oct 8;11(1):95. doi: 10.1186/s13000-016-0545-8.
Diagn Pathol. 2016.
PMID: 27717372
Free PMC article.
Clinical Trial.
Item in Clipboard
Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
Bedke J, Black PC, Szabados B, Guerrero-Ramos F, Shariat SF, Xylinas E, Brinkmann J, Blake-Haskins JA, Cesari R, Redorta JP.
Bedke J, et al. Among authors: blake haskins ja.
Urol Oncol. 2023 Dec;41(12):461-475. doi: 10.1016/j.urolonc.2023.10.004. Epub 2023 Nov 14.
Urol Oncol. 2023.
PMID: 37968169
Free article.
Review.
Item in Clipboard
Thrombotic microangiopathy with targeted cancer agents.
Blake-Haskins JA, Lechleider RJ, Kreitman RJ.
Blake-Haskins JA, et al.
Clin Cancer Res. 2011 Sep 15;17(18):5858-66. doi: 10.1158/1078-0432.CCR-11-0804. Epub 2011 Aug 3.
Clin Cancer Res. 2011.
PMID: 21813634
Free PMC article.
Review.
Item in Clipboard
Cite
Cite